These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Equivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler. Lähelmä S; Sairanen U; Haikarainen J; Korhonen J; Vahteristo M; Fuhr R; Kirjavainen M J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):462-73. PubMed ID: 25757188 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic study for the establishment of bioequivalence of two inhalation treatments containing budesonide plus formoterol. Grekas N; Athanassiou K; Papataxiarchou K; Rizea Savu S; Silvestro L J Pharm Pharmacol; 2014 Dec; 66(12):1677-85. PubMed ID: 25109416 [TBL] [Abstract][Full Text] [Related]
6. An Exploration of Factors Affecting Ruzycki CA; Martin AR; Finlay WH J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):405-417. PubMed ID: 31418632 [No Abstract] [Full Text] [Related]
7. Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products. Olsson B; Borgström L; Lundbäck H; Svensson M J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):355-69. PubMed ID: 23421897 [TBL] [Abstract][Full Text] [Related]
8. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Newman SP; Pitcairn GR; Hirst PH; Bacon RE; O'Keefe E; Reiners M; Hermann R Eur Respir J; 2000 Jul; 16(1):178-83. PubMed ID: 10933104 [TBL] [Abstract][Full Text] [Related]
9. Using Filters to Estimate Regional Lung Deposition with Dry Powder Inhalers. Tavernini S; Farina DJ; Martin AR; Finlay WH Pharm Res; 2021 Sep; 38(9):1601-1613. PubMed ID: 34463937 [TBL] [Abstract][Full Text] [Related]
10. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler. Chrystyn H; Safioti G; Keegstra JR; Gopalan G Int J Pharm; 2015 Aug; 491(1-2):268-76. PubMed ID: 26043823 [TBL] [Abstract][Full Text] [Related]
11. Current Inhalers Deliver Very Small Doses to the Lower Tracheobronchial Airways: Assessment of Healthy and Constricted Lungs. Walenga RL; Longest PW J Pharm Sci; 2016 Jan; 105(1):147-59. PubMed ID: 26852850 [TBL] [Abstract][Full Text] [Related]
12. Validating Whole-Airway CFD Predictions of DPI Aerosol Deposition at Multiple Flow Rates. Longest PW; Tian G; Khajeh-Hosseini-Dalasm N; Hindle M J Aerosol Med Pulm Drug Deliv; 2016 Dec; 29(6):461-481. PubMed ID: 27082824 [TBL] [Abstract][Full Text] [Related]
13. Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways. Longest PW; Tian G; Walenga RL; Hindle M Pharm Res; 2012 Jun; 29(6):1670-88. PubMed ID: 22290350 [TBL] [Abstract][Full Text] [Related]
14. Bioequivalence of budesonide plus formoterol (BF) Spiromax® and BF Turbohaler® (with and without charcoal block) in healthy volunteers. Weisfeld L; Shu Y; Shah TP Int J Clin Pharmacol Ther; 2015 Jul; 53(7):593-602. PubMed ID: 26042485 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of efficacy and safety of budesonide delivered via two dry powder inhalers. Kerwin EM; Pearlman DS; de Guia T; Carlsson LG; Gillen M; Uryniak T; Simonson SG Curr Med Res Opin; 2008 May; 24(5):1497-510. PubMed ID: 18419878 [TBL] [Abstract][Full Text] [Related]
16. Effect of particle deposition density of dry powders on the results produced by an in vitro test system simulating dissolution- and absorption rates in the lungs. Malmlöf M; Nowenwik M; Meelich K; Rådberg I; Selg E; Burns J; Mascher H; Gerde P Eur J Pharm Biopharm; 2019 Jun; 139():213-223. PubMed ID: 30862480 [TBL] [Abstract][Full Text] [Related]
17. Effect of the pulmonary deposition and in vitro permeability on the prediction of plasma levels of inhaled budesonide formulation. Salar-Behzadi S; Wu S; Mercuri A; Meindl C; Stranzinger S; Fröhlich E Int J Pharm; 2017 Oct; 532(1):337-344. PubMed ID: 28890175 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143 [TBL] [Abstract][Full Text] [Related]
19. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers. Munzel U; Marschall K; Fyrnys B; Wedel M Curr Med Res Opin; 2005 Jun; 21(6):827-33. PubMed ID: 15969882 [TBL] [Abstract][Full Text] [Related]